These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34820342)

  • 1. Tocilizumab in Systemic Juvenile Idiopathic Arthritis: Response Differs by Disease Duration at Medication Initiation and by Phenotype of Disease.
    Yan X; Tang W; Zhang Z; Zhang Y; Luo C; Tang X
    Front Pediatr; 2021; 9():735846. PubMed ID: 34820342
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparisons of the outcomes between early and late tocilizumab treatment in systemic juvenile idiopathic arthritis.
    Pacharapakornpong T; Vallibhakara SA; Lerkvaleekul B; Vilaiyuk S
    Rheumatol Int; 2017 Feb; 37(2):251-255. PubMed ID: 27798725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-Term Outcomes and Predictors of Effectiveness of Tocilizumab in Systemic Juvenile Idiopathic Arthritis: A Prospective Cohort Study.
    Nada DW; Moghazy A; Allam AE; Alunno A; Ibrahim AM
    Front Med (Lausanne); 2021; 8():665028. PubMed ID: 34041254
    [No Abstract]   [Full Text] [Related]  

  • 4. Correlations between serum interleukin 6, serum soluble interleukin 6 receptor, and disease activity in systemic juvenile idiopathic arthritis patients treated with or without tocilizumab.
    Vilaiyuk S; Lerkvaleekul B; Soponkanaporn S; Setthaudom C; Buranapraditkun S
    Cent Eur J Immunol; 2019; 44(2):150-158. PubMed ID: 31530985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis.
    Kostik MM; Dubko MF; Masalova VV; Snegireva LS; Kornishina TL; Chikova IA; Isupova EA; Kuchinskaya EM; Glebova NI; Buchinskaya NV; Kalashnikova OV; Chasnyk VG
    Pediatr Rheumatol Online J; 2015; 13():4. PubMed ID: 25685108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab-induced hypofibrinogenemia in patients with systemic-onset juvenile idiopathic arthritis.
    He T; Ling J; Yang J
    Sci Rep; 2023 Jun; 13(1):9050. PubMed ID: 37270663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective therapy of tocilizumab on systemic juvenile idiopathic arthritis-associated refractory macrophage activation syndrome.
    Wu J; Sun L; Tang X; Zheng Q; Guo L; Xu L; Li Y; Lu M
    Mod Rheumatol; 2022 Oct; 32(6):1114-1121. PubMed ID: 34971386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reasons for inactive disease and flare in systemic onset juvenile idiopathic arthritis patients during tocilizumab treatment.
    Kostik MM; Isupova EA; Chikova IA; Dubko MF; Masalova VV; Snegireva LS; Kalashnikova OV; Chasnyk VG
    Clin Exp Rheumatol; 2018; 36(2):335-341. PubMed ID: 29303703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab-induced anaphylaxis in patients with adult-onset Still's disease and systemic juvenile idiopathic arthritis: a case-based review.
    Park EH; Lee EY; Shin K; Kim HA
    Rheumatol Int; 2020 May; 40(5):791-798. PubMed ID: 31598752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
    Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
    J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for hypersensitivity reactions to tocilizumab introduction in systemic juvenile idiopathic arthritis.
    Yasuoka R; Iwata N; Abe N; Kohagura T; Nakaseko H; Shimizu M; Kawabe S
    Mod Rheumatol; 2019 Mar; 29(2):324-327. PubMed ID: 29578355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis.
    Aoki C; Inaba Y; Choe H; Kaneko U; Hara R; Miyamae T; Imagawa T; Mori M; Oba MS; Yokota S; Saito T
    J Rheumatol; 2014 Jun; 41(6):1171-7. PubMed ID: 24786929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis.
    Brunner HI; Ruperto N; Ramanan AV; Horneff G; Minden K; Calvo Penades I; Alexeeva E; Cleary G; Stern SM; Kone-Paut I; Maldonado Velázquez MDR; Rabinovich CE; Remesal A; Silva CA; Nikishina I; Zucchetto M; Brockwell L; Gordon O; Nagel S; De Benedetti F;
    Rheumatology (Oxford); 2024 Sep; 63(9):2535-2546. PubMed ID: 38552315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serious adverse events in children with juvenile idiopathic arthritis and other rheumatic diseases on tocilizumab - a real-world experience.
    Aeschlimann FA; Dumaine C; Wörner A; Mouy R; Wouters C; Melki I; Uettwiller F; Job-Deslandre C; Quartier P; Bader-Meunier B
    Semin Arthritis Rheum; 2020 Aug; 50(4):744-748. PubMed ID: 32526594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Shimizu M; Mizuta M; Okamoto N; Yasumi T; Iwata N; Umebayashi H; Okura Y; Kinjo N; Kubota T; Nakagishi Y; Nishimura K; Mohri M; Yashiro M; Yasumura J; Wakiguchi H; Mori M
    Pediatr Rheumatol Online J; 2020 Jan; 18(1):2. PubMed ID: 31924225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of disease course in systemic juvenile idiopathic arthritis.
    Kaplan MM; Tekin ZE; Çelikel E; Güngörer V; Karagöl C; Öner N; Polat MC; Öztürk D; Özçelik E; Ekici MI; Acar BÇ
    Mod Rheumatol; 2024 Apr; ():. PubMed ID: 38590038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis.
    Pardeo M; Wang J; Ruperto N; Alexeeva E; Chasnyk V; Schneider R; Horneff G; Huppertz HI; Minden K; Onel K; Zemel L; Martin A; Koné-Paut I; Siamopoulou-Mavridou A; Silva CA; Porter-Brown B; Bharucha KN; Brunner HI; De Benedetti F;
    J Rheumatol; 2019 Sep; 46(9):1117-1126. PubMed ID: 30824645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab in the treatment of systemic-onset juvenile idiopathic arthritis - single-centre experience.
    Roszkiewicz J; Orczyk K; Smolewska E
    Reumatologia; 2018; 56(5):279-284. PubMed ID: 30505008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.
    Tappeiner C; Mesquida M; Adán A; Anton J; Ramanan AV; Carreno E; Mackensen F; Kotaniemi K; de Boer JH; Bou R; de Vicuña CG; Heiligenhaus A
    J Rheumatol; 2016 Dec; 43(12):2183-2188. PubMed ID: 27633821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study.
    Ayaz NA; Karadağ ŞG; Koç R; Demirkan FG; Çakmak F; Sönmez HE
    Rheumatol Int; 2020 Jul; 40(7):1111-1116. PubMed ID: 32417938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.